Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
NEJM 380:1906-1917, Diener, H.C.,et al, 2019
Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 377:1033-1042,1006,1093, Sondergaard, L.,et al, 2017
Closure Versus Medical Therapy for Preventing Recurrent Stroke in Patients with Patent Foramen Ovale and a History of Cryptogenic Stroke or Transient Ischemic Attack
Stroke 47:e188-e189, Li, J.,et al, 2016
Lambls Excrescense Associated with Cryptogenic Stroke
Am J Case Rep 16:876-881, Chu, A.,et al, 2015
Internal Carotid Artery Dissection and Asymmetrical Facial Flushing
Stroke 45:e78-e80, Drexler, I.,et al, 2014
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Stroke 43:422-431, Kitsios,G.D.,et al, 2012
Insufficient Platelet Inhibition is Related to Silent Embolic Cerebral Infarctions After Coronary Angiography
Stroke 43:727-732, Kim,B.J.,et al, 2012
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
NEJM 366:991-999,1048, Furlan,A.J.,et al, 2012
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:227-276, Furie,K.L.,et al, 2011
An unusual cause of stroke and hypoxia
BMJ 342:c7200, Bell, S.L. & Eveson, D.J., 2011
Study Design of the CLOSURE I Trial: A Prospective, Multicenter, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex Septal Closure System Versus Best Medical Therapy in Patients With Stroke or TIA Due to Presumed Paradoxical Embolism Through a PFO
Stroke 41:2872-2883, Furlan,A.J.,et al, 2010
Recurrent Cerebral Ischemia in Medically Treated Patent Foramen Ovale: A Meta-Analysis
Neurol 73:89-97,84, Almekhlafi,M.A.,et al, 2009
Antithrombotic and Interventional Treatment Options in Cardioembolic Transient Ischaemic Attack and Ischaemic Stroke
JNNP 78:14-24, McCabe,D.J.H. &Rakhit,R.D., 2007
Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack
Stroke 37:577-617, Sacco,R.L.,et al, 2006
Vertebrobasilar Disease
NEJM 352:2618-2626, Savitz,S.I.&Caplan,L.R., 2005
Patent Foramen Ovale and Recurrent Stroke: Closure is the Best Option: No
Stroke 35:804-805,806, Tong,D.C. &Becker,K.J., 2004
Patent Foramen Ovale and Recurrent Stroke: Closure is the Best Option: Yes
Stroke 35:803-804,806, Furlan,A.J., 2004
Age As a Determinant of Adverse Events in Medically Treated Cryptogenic Stroke Patients with Patent Foramen Ovale
Stroke 35:2145, Homma,S.,et al, 2004
Should Stroke Subtype Influence Anticoagulation Decisions to Prevent Recurrence in Stroke Patients with Atrial Fibrillation?
Stroke 32:2828-2832, Evans,A.,et al, 2001
Stroke in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction
Neurol 54:288-294, Pullicini,P.M.,et al, 2000
Primary Prevention of Arterial Thromboembolism in Non-Rheumatic Atrial Fibrillation in Primary Care:Randomised Controlled Trial Comparing Two Intensities of Coumarin with Aspirin
BMJ 319:958-964, Hellemons,B.S.P.,et al, 1999
Fixed Minidose Warfarin & Aspirin Alone & in Comb vs Adjusted-Dose Warfarin for Stroke Prevent in Atrial Fib
Arch Int Med 158:1513-1521, 14871998., Gullov,A.L.,et al, 1998
Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation
Neurol 51:674-681, Hart,R.G.,et al, 1998
Patent Foramen Ovale and Brain Infarct:Echocardiographic Predictors, Recurrence, and Prevention
Stroke 25:782-786, Hanna,J.P.,et al, 1994
Antithrombotic Therapy in Cerebrovascular Disease
Ann Int Med 115:885-895, Rothrock,J.F.&Hart,R.G., 1991
Stroke Prevention in Nonvalvular Atrial Fibrillation:A Review of Prospective Randomized Trials
Ann Neurol 30:511-518, Albers,G.W.,et al, 1991
Stroke Prevention in Nonvalvular Atrial Fibrillation
Ann Int Med 115:727-736, Albers,G.W.,et al, 1991
Physicians'Attitudes Toward Anticoag & Antiplat Agents for Stroke Prevent in Elderly Pts with Atrial Fib
Arch Int Med 151:1950-1953, 19221991., Kutner,M.,et al, 1991
Placebo-Controlled, Randomised Trial of Warfarin & ASA for Prevention of Thromboembolic Complic in Chronic A Fib
Lancet 1:175-179, Petersen,P.,et al, 1989
Cerebral Ischemia with Mitral Valve Prolapse
Am Heart J 113:1308-1315, Wolf,P.A.,et al, 1987